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Abstract. 
 
Keratinocyte proliferation and migration are
essential to cutaneous wound healing and are, in part,
mediated in an autocrine fashion by epidermal growth
factor receptor (EGFR)–ligand interactions. EGFR
ligands are initially synthesized as membrane-anchored
forms, but can be processed and shed as soluble forms.
We provide evidence here that wound stimuli induce
keratinocyte shedding of EGFR ligands in vitro, partic-
ularly the ligand heparin-binding EGF-like growth fac-
tor (HB-EGF). The resulting soluble ligands stimulated
transient activation of EGFR. OSU8-1, an inhibitor of
EGFR ligand shedding, abrogated the wound-induced
activation of EGFR and caused suppression of kerati-
nocyte migration in vitro. Soluble EGFR–immunoglob-
 
ulin G-Fc
 
g
 
 fusion protein, which is able to neutralize all
EGFR ligands, also suppressed keratinocyte migration
in vitro. The application of OSU8-1 to wound sites in
mice greatly retarded reepithelialization as the result of
a failure in keratinocyte migration, but this effect could
be overcome if recombinant soluble HB-EGF was
added along with OSU8-1. These ﬁndings indicate that
the shedding of EGFR ligands represents a critical
event in keratinocyte migration, and suggest their pos-
sible use as an effective clinical treatment in the early
phases of wound healing.
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Introduction
 
Successful wound healing involves a number of processes
including inflammation, cell proliferation, cell migration,
vascular permeability and angiogenesis, as well as matrix
deposition and tissue remodeling (for review see Martin,
1997). Particularly critical are cell proliferation and migra-
tion, which are driven by growth factors and cytokines re-
leased coordinately into the injury sites. In cutaneous
wound healing, keratinocytes play a central role, not only
as a key structural cell type in the repairing skin, but also
as the source of a number of growth factors. Prominent
among these keratinocyte-derived factors are ligands for
the epidermal growth factor receptor (EGFR)
 
1
 
.
 
The EGFR ligand family is composed of six members in-
cluding the epidermal growth factor (Cohen, 1964), trans-
 
forming growth factor-
 
a
 
 (TGF-
 
a
 
; Derynck et al., 1984),
amphiregulin (AR; Shoyab et al., 1989), heparin-binding
EGF-like growth factor (HB-EGF; Higashiyama et al.,
1991), betacellulin (Shing et al., 1993), and epiregulin (Toy-
oda et al., 1995). All members of this family are synthe-
sized as membrane-anchored forms, which are then pro-
cessed to give bioactive soluble factors. This processing can
be stimulated by treating cells with various agents, includ-
 
ing the phorbol ester 12-
 
O
 
-tetradecanoylphorbol-13-ace-
tate (TPA; for review see Massague and Pandiella, 1993).
Within the EGFR ligand family, TGF-
 
a
 
, AR, and HB-
EGF have been extensively characterized and clearly
shown to be autocrine growth factors for keratinocytes
(Coffey et al., 1987; Cook et al., 1991; Hashimoto et al.,
1994). The transmembrane forms of these factors are also
capable of stimulating the growth of adjacent cells includ-
ing keratinocytes via cell–cell contact, a process termed
juxtacrine stimulation (Brachmann et al., 1989; Wong et
al., 1989; Higashiyama et al., 1995; Goishi et al., 1995; Inui
et al., 1997).
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Abbreviations used in this paper:
 
 ADAM, a disintegrin and metallopro-
tease; AP, alkaline phosphatase; AR, amphiregulin; ECL, enhanced chemilu-
minescence; EGFR, epidermal growth factor receptor; EGFR-Fc, epidermal
growth factor receptor–immunoglobulin G-Fc
 
g
 
 fusion protein; HB-EGF,
heparin-binding EGF-like growth factor; MMP, matrix metalloprotease;
 
TACE, tumor necrosis factor–
 
a
 
 converting enzyme; TGF-
 
a
 
, transforming
growth factor–
 
a
 
; TPA, 12-
 
O
 
-tetradecanoylphorbol-13-acetate. 
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Marikovsky et al. (1993) reported that wound fluid in
skin contains processed bioactive EGFR ligands, suggest-
ing that regulation of EGFR ligand shedding might be a
physiologically important event in wound healing. There-
fore, we investigated the possible role of EGFR ligand
shedding in response to wounding, focusing in particular
on the early EGFR-related molecular events which are
evoked by wound stimuli. We also applied a newly estab-
lished inhibitor of EGFR ligand shedding to wound heal-
ing models, in both in vitro and in vivo experiments.
 
Materials and Methods
 
Materials
 
Human EGFR antibodies were purchased from Upstate Biotechnology.
Phosphotyrosine antibody PY-20 was obtained from Transduction Labora-
tories. Neutralizing polyclonal antibody No. 197 was raised in a goat against
a 75–amino acid form of recombinant human HB-EGF and was obtained
from D. Damm (Scios Inc., Mountain View, CA; Hashimoto et al., 1994).
Anti-EGFR neutralizing antibody was a generous gift from Dr. U. Rodeck
(Wister Institute, Philadelphia, PA). AG1478 was obtained from Calbio-
chem. TPA was obtained from Wako Pure Chemical Industry. Sulfo-NHS-
biotin was purchased from Pierce Chemical Co. An enhanced chemilumi-
nescence (ECL) kit was obtained from Amersham Pharmacia Biotech. 
 
Metalloprotease Inhibitors
 
More than five hundred hydroxamic acid–based inhibitors of metallopro-
teases, along with a series of nonhydroxamic derivatives, were synthesized
by Kanebo Ltd. The hydroxamic acid–based inhibitors included the fol-
lowing: OSU8-1, [4-(
 
N
 
-hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-
 
L
 
-3-(5,6,7,8-tetra-hydro-1-naphthyl)alanine-
 
N
 
-methylamide; OSU7-6, [4-
(
 
N
 
-hydroxyamino)-2R-isobutylsuccinyl]-
 
L
 
-3-(1-naphthyl)-alanine-
 
N
 
-meth-
ylamide; and OSU9-6, [6,7-dihydroxy-3-(
 
N
 
-hydroxycarbamoyl)-2-(4-meth-
oxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline]. OSU8-1, OSU7-6, and
OSU9-6 work as competitive inhibitors.
 
Construction of Alkaline Phosphatase–EGF-Related 
Ligand Fusion Vectors
 
The coding region for human placental alkaline phosphatase (AP) was ob-
tained from the APtag-1 expression vector (a gift from Dr. J. Flanagan,
Harvard Medical School, Boston, MA) and inserted into the multiple
cloning site of pRc/CMV (Invitrogen). A BstBI-MscI fragment of the hu-
man HB-EGF cDNA, which encodes the signal sequence and prose-
quence, was fused to the 5
 
9
 
 end of the AP sequence to create the plasmid
pSS-AlPh (see Fig. 1 a). As pSS-AlPh has a unique HpaI site overlapping
the termination codon of the AP coding region, one of the following DNA
fragments encoding human EGF–related ligands were fused in-frame at
this site: MscI-PstI fragment of the HB-EGF cDNA (0.45 kb); HinfI frag-
ment of the AR cDNA (0.5 kb); or MseI-SauIII fragment of the TGF-
 
a
 
cDNA (0.38 kb). The plasmids resulting from these ligations were intro-
duced into CHO cells using the calcium phosphate method (Chen and
Okayama, 1988), and stably transfected clones were isolated.
 
Cell-surface Biotinylation, Immunoprecipitation, and 
Western Blotting
 
CHO cell transfectants stably expressing either wild-type HB-EGF, AR,
or TGF-
 
a
 
, or AP-tagged fusions of these ligands, were seeded in 6-cm
dishes at a density of 2 
 
3
 
 10
 
5
 
 cells/dish and cultured for 24 h with Ham’s
F12/10% FCS. Cells were washed three times with ice-cold Hanks buffer
and biotinylated with 0.1 mg/ml of sulfo-NHS-biotin in 50 mM Hepes, pH
7.5, and 0.15 M NaCl for 15 min on ice. Excess reagent was quenched and
removed by washing with ice-cold Ham’s F12/10% FCS. Cells were lysed
with a buffer containing 1% Triton X-100, 3 mM EDTA, 1 mM (
 
p
 
-amidi-
nophenyl) methanesulfonyl fluoride HCl, 1 
 
m
 
g/ml aprotinin, 5 
 
m
 
M 3,4-
dichloroisocoumarin, and 0.4 M NaCl in 20 mM Hepes, pH 7.2. After cen-
trifugation of the lysates at 15,000 rpm for 15 min, supernatants were col-
lected and incubated with 2 
 
m
 
g of human placental alkaline phosphatase
antibody (Dako), HB-EGF antibody No. H6 (Higashiyama et al., 1995),
 
AR antibody No. AAR1 (Hashimoto et al., 1994), or TGF-
 
a
 
 antibody (a
gift from Dr. R. Derynck, University of California, San Francisco, San
Francisco, CA) for 2 h at 4
 
8
 
C, followed by incubation with 10 
 
m
 
l of protein
A trisacryl (50% suspension; Pierce Chemical Co.) for 2 h at 4
 
8
 
C. After
centrifugation of the mixes, the pellets were analyzed by SDS-PAGE and
Western blotting as described previously (Goishi et al., 1995).
 
Preparation of EGFR Extracellular
Domain–Immunoglobulin G-Fc
 
g
 
 Fusion Protein
 
A fusion protein consisting of the extracellular domain of EGFR and hu-
man immunoglobulin G-Fc
 
g
 
 (EGFR-Fc) was produced as follows. A
BglII site was engineered into an EGFR expression plasmid (Gotoh et al.,
1994) at the point encoding the extracellular domain/transmembrane do-
main junction of this receptor. A SacI-BglII fragment encoding the extra-
cellular domain of EGFR was isolated from the resulting plasmid and
fused to the 5
 
9
 
 end of the coding region for IgFc in pcDNA-Fc
 
g
 
 (a gift
from Dr. H. Ishiguro, Fujita Health University, Aichi, Japan). The plas-
mid obtained as a result of this ligation was introduced into CHO cells us-
ing the calcium phosphate method (Chen and Okayama, 1988). A stable
transfectant was cloned, amplified, and incubated in the presence of se-
rum-free medium. EGFR-Fc fusion protein was purified from the result-
ing conditioned medium using a protein A column (5 ml Pharmacia Hi-
Trap) on an FPLC system.
 
Screening of EGFR Ligand Shedding Inhibitors
 
Stable transfectants expressing AP-tagged EGFR ligands were seeded in
96-well plates at a density of 2 
 
3
 
 10
 
4
 
 cells/well and incubated for 24 h. The
cells were washed with Mg
 
1
 
 and Ca
 
2
 
1
 
-free PBS [PBS(
 
2
 
)] and incubated
for 10 min with 1 
 
m
 
M of an inhibitor. TPA (60 nM) was added to stimulate
inducible processing, and the plates were incubated for a further 30 min.
100-
 
m
 
l aliquots of the conditioned media were transferred to 96-well
plates and heated for 10 min at 65
 
8
 
C to inactivate endogenous alkaline
phosphatases. An equal volume of 2
 
3
 
 AP buffer (2 M diethanolamine,
pH 9.8, 1 mM MgCl
 
2
 
, 20 mM 
 
L
 
-homoarginine, and 24 mM 
 
p
 
-nitrophe-
nylphosphate) was added to each well and gently mixed at room tempera-
ture until color development was apparent in positive control wells. AP
activity was determined by the measurement of absorbance at 405 nm
with a microplate reader.
 
Keratinocyte Culture and Wound Assay
 
Human keratinocytes were cultured in optimized nutrient medium
MCDB153 (Nissui Co.) supplemented with 5 
 
m
 
g/ml insulin, 0.5 
 
m
 
M hydro-
cortisone, 0.1 mM ethanolamine, 0.1 mM phosphoethanolamine, and 150
 
m
 
g/ml bovine hypothalmic extract (BHE) as previously described (Hash-
imoto et al., 1994). The stock solution of MCDB153 used in this case was
supplemented with 0.1 mM CaCl
 
2
 
, and contained elevated concentrations
of amino acids (0.75 mM isoleucine, 0.24 mM histidine, 0.09 mM phenyla-
lanine, 0.045 mM tryptophan, and 0.075 mM tyrosine) and kanamycin (0.1
mg/ml).
For wounding experiments, cells were seeded on type I collagen–
coated 10-cm dishes or 6-well plates. After reaching subconfluency, the
cells were re-fed with a BHE-free medium and wounded in either of two
ways. To obtain conditioned media from wounded keratinocytes, cell lay-
ers were wounded by linear, cross-stripe scrapes 5 mm apart using the tip
of a micropipette (tip-scraping). For the growth and migration assay, cell
layers were scraped with a wide silicone rubber cell scraper (rubber scrap-
ing). In either case, the cells were washed with fresh medium once to re-
move floating cells and re-fed with fresh medium without BHE in the ab-
sence or presence of EGFR neutralizing antibody No. 425 (10 
 
m
 
g/ml),
AG1478 (30 nM), OSU8-1 (1 
 
m
 
M), or HB-EGF (20 ng/ml). The condi-
tioned media from these cultures were collected for analysis after various
periods of incubation at 37
 
8
 
C.
 
Growth Factor Activity Assays
 
To measure the mitogenic activities of EGFR ligands, an EP170.7 cell
growth factor assay was carried out as described previously (Blotnick et
al., 1994). Cells were plated in 96-well plates (2 
 
3
 
 10
 
4
 
 cells/100 
 
m
 
l/well).
100-
 
m
 
l aliquots of samples were added to each well, and the plates were
incubated for 36 h. [
 
3
 
H]Thymidine (1 
 
m
 
Ci/well; 1 mCi 
 
5 
 
37 MBq) was
added to the wells, and the plates were incubated for an additional 6 h.
The EP170.7 cells were harvested and analyzed for the incorporation of
[
 
3
 
H]thymidine into DNA using a 1205 Betaplate system (Amersham Phar- 
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macia Biotech). To neutralize HB-EGF activity, samples were preincu-
bated with human HB-EGF neutralizing antibody No. 197 at a final con-
centration of 10 
 
m
 
g/ml before addition to the assay wells.
A juxtacrine growth factor assay was carried out as described previ-
ously (Higashiyama et al., 1995). Keratinocytes (10
 
5
 
 cells/well) were
plated in 24-well plates and incubated for 12 h. The cell layers were
washed with fresh medium containing 2 M NaCl to remove soluble HB-
EGF and AR trapped by cell-surface heparan sulfate proteoglycans, and
were then fixed with 5% buffered formalin for 5 min. The fixed cells were
washed twice with RPMI 1640/10% FCS, and EP170.7 cells (10
 
5
 
 cells/500
 
m
 
l/well) were added to the wells along with [
 
3
 
H]thymidine. After a 6-h in-
cubation, the EP170.7 cells were harvested and analyzed for incorporation
of [
 
3
 
H]thymidine into DNA.
 
Northern Blot Hybridization
 
Total RNA was isolated from primary cultured human keratinocytes as
described previously (Chomczynski and Sacchi, 1987). Total RNA was
electrophoresed on a 1% agarose gel and transferred onto a Zeta-probe
membrane (Bio-Rad Laboratories) by capillary action. The membrane fil-
ter was hybridized with 
 
32
 
P-labeled human HB-EGF, AR, or TGF-
 
a
 
cDNA probes that corresponded to the HindIII-XbaI, ApaI-XbaI, and
HindIII-XbaI fragments, respectively. The filter was washed once in 2
 
3
 
SSC, 0.1% SDS, and then twice in 0.2
 
3
 
 SSC, 0.1% SDS at 55
 
8
 
C, before
exposure to a scientific imaging film (Eastman Kodak Co.).
 
Migration Assay
 
The migration of keratinocytes was assayed in a Boyden chamber as pre-
viously described (Boyden, 1962; Higashiyama et al., 1993). Keratinocytes
(5 
 
3
 
 10
 
5
 
 cells/dish) were plated on type I collagen–coated 10-cm dishes
and incubated for 72 h. The subconfluent keratinocytes were detached
from the dishes by incubation with trypsin-EDTA (0.05% trypsin and 0.5
mM EDTA) at 37
 
8
 
C. To avoid excess exposure to trypsin, the incubation
was carried out for 1 min or less. The cells were washed once with the sup-
plemented MCDB153 medium described above, resuspended in the same
medium, and diluted to a final cell concentration of 10
 
5
 
 cells/ml. To set up
the migration assay, samples were added to the bottom wells of a 48-well
Boyden chamber (Neuro Probe Inc.) and an 8-
 
m
 
m pore size polyvinylpyr-
rolidone-free polycarbonate membrane (Neuro Probe Inc.) precoated
with type I collagen (10 
 
m
 
g/ml in PBS; Nitta Gelatin Co.) was placed
above these wells. 50 
 
m
 
l of the keratinocyte suspension were added to
each upper well of the 48-well chamber, and the chamber was incubated
for 4 h at 37
 
8
 
C in a humidified atmosphere of air/5% CO
 
2
 
. Cells adhering
to the upper surface of the filter membrane were removed by scraping
with a rubber blade. Cells that had migrated through the filter were fixed
with buffered formalin overnight, and then stained with Gill’s hematoxy-
lin overnight. The filter was mounted between two glass slides with 90%
glycerol, and the number of keratinocytes that had crossed the filter in
each well was determined by counting the stained keratinocytes under a
microscope.
 
Immunoprecipitations and Phosphotyrosine
Western Blotting
 
Keratinocytes (5 
 
3
 
 10
 
5
 
 cells/dish) were plated on type I collagen–coated
10-cm dishes and incubated for 72 h. The subconfluent keratinocytes were
starved for 2 h in BHE-free medium with or without 1 
 
m
 
M of OSU8-1, 50
 
m
 
M of cycloheximide, or 10 
 
m
 
g/ml HB-EGF neutralizing antibody No.
197, and then wounded by tip-scraping followed by incubation for the in-
dicated times at 37
 
8
 
C. Lysates were prepared in 1 ml of PBS(
 
2
 
) contain-
ing 5 mM EDTA, 100 
 
m
 
M sodium orthovanadate, 100 
 
m
 
M sodium pyro-
phosphate, 1 mM sodium fluoride, 5 
 
m
 
M 3,4-dichloroisocumarin, 1 mg/ml
aprotinin, and 1% Triton X-100. Cell lysates were centrifuged at 10,000
rpm for 10 min at 4
 
8
 
C and the supernatants were incubated with 1 
 
m
 
g of
anti-EGFR antibodies for 12 h at 4
 
8
 
C with end-over-end rotation. 15 
 
m
 
l of
protein A–Sepharose (50% suspension; Amersham Pharmacia Biotech)
were added to each lysate/antibody mixture and incubated for 12 h at 4
 
8
 
C
with end-over-end rotation. The mixtures were centrifuged and the pro-
tein A–Sepharose beads were washed three times with lysis buffer, resus-
pended in 20 
 
m
 
l of 2
 
3
 
 SDS-PAGE sample buffer (0.5 M Tris-HCl, pH 7.2,
1% SDS, 100 mM 
 
b
 
-mercaptoethanol, and 0.01% bromophenol blue), and
boiled for 5 min. Aliquots of the boiled samples were fractionated on 6%
SDS-PAGE gels and were transferred to PVDF membranes (Millipore
Corporation). The PVDF membranes were blocked with 5% skimmed
milk in PBS(
 
2
 
) overnight at 4
 
8
 
C. The membranes were incubated for 6 h
with a second antibody as indicated in the text and figures. After three
washes with 0.05% Tween 20 in PBS(
 
2
 
) at 10-min intervals, the mem-
branes were treated with ABC reagents (Vector Laboratories) for 20 min
at room temperature. The membranes were again washed three times with
0.05% Tween 20 in PBS(
 
2
 
), and were treated with ECL detection re-
agents for 1 min at room temperature before exposure to scientific imag-
ing films (Eastman Kodak Co.).
 
In Vivo Wound Assay
 
An in vivo wound assay was performed as previously described (Tsuboi et
al., 1992). Female BALB/c mice (
 
n
 
 5 
 
15) were housed individually and
used at 8 wk of age. A vehicle solution, consisting of 1.5% carboxymethyl-
cellulose in sterilized PBS solution, was used for the control. OSU8-1
alone (10 mM) and a cocktail of 10 mM OSU8-1 plus 5 
 
m
 
g/ml HB-EGF
were prepared in the same solution. Mice were anesthetized with diethyl-
ether, and two full-thickness-round wounds were prepared on the back of
each mouse with a punch biopsy instrument (6-mm diam). After the oper-
ation, 500 
 
m
 
l of the test solution was applied to each wound. One wounded
side of each mouse was used for vehicle treatment, whereas the other side
received either OSU8-1 treatment (
 
n 5 10) or a cocktail treatment of
OSU8-1 and HB-EGF (n 5 5). The wounds were left open, and the mice
were treated daily with these reagents for 5 d. The mice were killed at day
6, and the wounds were excised and fixed in 10% buffered formalin. After
fixation, the samples were sectioned parallel to the anterior-posterior axis
and stained with antikeratin/cytokeratin antibody (Nichirei Ltd.).
Results
Screening and Characterization of Inhibitors for EGFR 
Ligand Shedding
Expression plasmids encoding fusions between AP and
three different EGFR ligands (AP-tag HB-EGF, AP-tag
AR, and AP-tag TGF-a) were constructed as shown in
Fig. 1 (a and b), and were stably transfected into CHO
cells. Fusion protein expression on the surface of the trans-
fected cells was analyzed by cell-surface biotinylation fol-
lowed by immunoprecipitation with an anti-AP antibody.
Proteins of the expected size (z88 kD) were expressed al-
most equally in the respective transfected cell lines (Fig. 1
c). To determine whether the fusions could be processed
to release soluble versions of the AP-tagged ligands, TPA-
inducible shedding of these ligands was tested. AP activity
in the conditioned media of the three transfectants was
measured after a 30-min incubation with or without 60 nM
TPA. TPA induced the shedding of AP-tag HB-EGF and
AP-tag TGF-a (Fig. 1 d), which is consistent with previous
observations on TPA-stimulated shedding (Pandiella and
Massague, 1991; Goishi et al., 1995). However, TPA was
less effective, at inducing the shedding of AP-tag AR (Fig.
1 d). The shed ligands were also able to activate the EGF
receptor (data not shown).
Using the AP-tag EGFR ligand transfectants, .500 syn-
thetic compounds were tested for the ability to inhibit
shedding of the ligands. Since it has been reported that a
matrix metalloprotease (MMP) is involved in the shedding
of HB-EGF and TGF-a (Suzuki et al., 1997; Izumi et al.,
1998; Peschon et al., 1998), these compounds were de-
signed as potential MMP inhibitors. The most effective
compound was OSU8-1. 1 mM OSU8-1 markedly blocked
the shedding of AP-tag HB-EGF and AP-tag AR, and
partially blocked the shedding of AP-tag TGF-a (Fig. 2 a).
A 10-fold higher concentration of OSU8-1 (10 mM) signif-
icantly blocked the TPA-inducible shedding of all three
AP-tagged EGFR ligands (Fig. 2 a). Cell-surface biotin-The Journal of Cell Biology, Volume 151, 2000 212
ylation and immunoprecipitation of wild-type HB-EGF,
TGF-a, and AR also revealed the abrogation of their
TPA-inducible shedding by 10 mM of OSU8-1 (Fig. 2 b).
We examined the inhibitory spectrum of OSU8-1 with re-
gard to the following three representative MMPs: MMP-1,
MMP-3, and MMP-9. As shown in Table I, OSU8-1 effec-
tively inhibited the activities of all three MMPs with IC50s
of 0.3–2.9 nM. We also selected two more compounds,
OSU9-6 and OSU7-6 that showed similar inhibitory activi-
ties for the shedding of EGFR ligands, but which dis-
played distinguishable inhibitory activities for the three
tested MMPs (Table I). These three inhibitors were used
for characterization of EGFR ligand shedding in the
wound experiments described below.
Wounding of Cultured Human Keratinocytes Induces 
the Production of Active and Soluble EGFR Ligands
To investigate EGFR ligand shedding in response to
wounding, subconfluent cultures of keratinocytes were
scraped with the tip of a micropipette. The production of
bioactive soluble EGFR ligands in conditioned medium
collected at different times after the wounding was deter-
mined using a DNA synthesis assay. Fig. 3 a shows a typi-
cal time course for the release of EGFR ligands in the
early phase after wounding (0–210 min). The production
of soluble EGFR ligands showed two peaks during this
time period, at 60 and 210 min after wounding. EGFR ac-
tivation in the wounded keratinocyte cultures themselves
was observed starting at 90 min after wounding. EGFR ac-
tivation continued for at least 60 min (90–150 min after
wounding) and was reactivated at 210 min (Fig. 3 b). Four
independent experiments showed almost identical pat-
terns of ligand production and EGFR activation. The ad-
dition of 1 mM OSU8-1 abrogated completely the release
of EGFR ligands and EGFR activation (Fig. 3, a and b).
Characterization of EGFR Ligands Produces by 
Keratinocytes in Response to Wounding
To investigate the identity of the shed EGFR ligands and
their origin at early times after wounding, Northern blot
analyses, inhibition of de novo protein synthesis by cyclo-
heximide, and neutralization experiments were carried
Figure 1. Expression of AP-tagged EGFR ligands. (a) Structure of the AP-tag parental expression plasmid, pSS-AlPh. (b) A schematic
diagram of the region within the expression plasmids derived from pss-AlPh that encode the fusions of AP-tag and EGFR ligands. The
coding region for the AP-tag HB-EGF fusion was constructed such that, in the encoded fusion, the AP sequence (488 amino acids) was
inserted at Ala84 of the HB-EGF precursor. In the AP-tag AR and AP-tag TGF-a fusion proteins, AR (residues 102–252) and TGF-a
(residues 45–160), respectively, were substituted for HB-EGF (residues 85–208). (c) Expression of AP-tag HB-EGF, AP-tag AR, and
AP-tag TGF-a on the surface of transfected CHO cells. Biotinylated AP-tag HB-EGF, AP-tag AR, and AP-tag TGF-a were immuno-
precipitated with human placental AP antibody and analyzed by SDS-PAGE and Western blotting. Biotinylated proteins on the West-
ern blot membranes were detected by HRP-conjugated avidin and ECL. (d) AP activity in the conditioned media of transfectants ex-
pressing AP-tag HB-EGF, AP-tag AR, and AP-tag TGF-a. Cells were treated with or without 60 nM TPA for 30 min at 378C. AP
activity was measured as described in Materials and Methods. Each bar is the average of triplicate values.Tokumaru et al. Ectodomain Shedding of HB-EGF in Wound Healing 213
out. In the early phase after wounding (0–6 h), little if any
enhancement of HB-EGF, AR, or TGF-a gene expression
was observed (Fig. 4 a). Cycloheximide failed to abrogate
the EGFR activation induced by wounding (Fig. 4 b).
These experiments indicated that the EGFR ligands were
shed from transmembrane forms that were preexisting in
the cells. HB-EGF neutralizing antibody No. 197 sup-
pressed the wound-induced activation of EGFR by z70%
(Fig. 4 b), suggesting that HB-EGF constitutes a major
portion of the shed EGFR ligands in the keratinocyte con-
ditioned medium.
To confirm which EGFR ligands are most susceptible to
shedding after wounding, stable transfectants of HaCat, a
keratinocyte cell line, which express almost equal amounts
of AP-tag HB-EGF, AP-tag AR, or AP-tag TGF-a were
subjected to a wound assay. The levels of soluble AP-tag
HB-EGF, AP-tag AR, and AP-tag TGF-a in the condi-
tioned medium were elevated 4.8-, 2.2-, and 1.3-fold, re-
spectively, by wound stimuli (Fig. 4 c). These results again
suggest that the transmembrane form of HB-EGF repre-
sents the major target for wound-induced EGFR ligand
processing, in that it is 3.2- and 12.7-fold more susceptible
to this processing than the precursors for AR and TGF-a,
respectively. 1 mM of OSU8-1 was effective at inhibiting
the shedding of AP-tag HB-EGF and also AP-tag AR, but
had no effect on wound-induced AP-tag TGF-a shedding
(Fig. 4 c).
Shedding of EGFR Ligands Is Essential for 
Keratinocyte Migration Induced by Wound Stimuli
Cultured keratinocytes grew and spread into a wound area
during a 3-d incubation as shown in Fig. 5. To confirm the
involvement of EGFR signaling in the wound-induced
growth and migration of these keratinocytes, EGFR neu-
tralizing antibody No. 425 or a tyrosine kinase inhibitor
specific for EGFR (tyrphostin AG1478) were introduced
into the wounded keratinocyte cultures. Cells treated with
antibody No. 425 or AG1478 were both suppressed in
terms of proliferation (to approximately 10–15% of the
control) and migration (Fig. 5; see also Fig. 7 b). We also
employed an EGFR-Fc fusion protein to neutralize all
EGFR ligands released by the keratinocytes, and achieved
a 70% inhibition of migration (Fig. 6 a). These data indi-
cate that EGFR activation and the subsequent molecular
signaling play an essential role in the wound-induced
growth and migration of keratinocytes. The addition of 1
mM OSU8-1 also significantly suppressed cell migration to
a level comparable to that seen with antibody No. 425 and
AG1478 (Fig. 5). In contrast, growth of the cells was not
suppressed to the extent observed for No. 425 and
AG1478 (only z50% inhibition as shown in Fig. 7 b). Col-
ony growth in the nonscraped area of the cultured kerati-
nocytes was observed in the presence of OSU8-1, again
suggesting that this compound is more effective in inhibit-
ing cell migration than cell growth. Cells treated with both
20 ng/ml of human recombinant HB-EGF and 1 mM of
Figure 2. Effect of OSU8-1 on TPA-inducible shedding of
EGFR ligands. (a) AP activities in the conditioned media of
CHO transfectants expressing AP-tag HB-EGF, AP-tag AR, and
AP-tag TGF-a treated with or without 60 nM of TPA in the pres-
ence or absence of OSU8-1. Cells were preincubated with the in-
dicated concentration of OSU8-1 for 10 min at 378C. The cells
were incubated with fresh media containing the indicated con-
centrations of TPA and OSU8-1 for 30 min at 378C. AP activity
was measured as described in Materials and Methods. Each bar is
the average of triplicate values. (b) CHO transfectants expressing
wild-type (non–AP-tag fused) HB-EGF, AR, and TGF-a were
biotinylated and preincubated with or without 10 mM OSU8-1
for 10 min at 378C. Cells were incubated with fresh media con-
taining the indicated concentrations of TPA and OSU8-1 for 30
min at 378C, followed by cell lysis, immunoprecipitation with an-
tibodies against the shed ligands, SDS-PAGE, Western blotting,
and avidin-HRP/ECL detection. The wild-type HB-EGF shows
different processing forms (Goishi et al., 1995).
Table I. Inhibition Spectra of EGFR-ligand
Shedding Inhibitors
Percent inhibition at 1 mM* IC50
‡
Compounds HB-EGF AR TGF-a MMP-1 MMP-3 MMP-9
nM nM nM
OSUB8-1 95 70 51 0.30 2.9 0.30
OSUB9-6 47 35 5 10,000 10,000 .1,000
OSUB7-6 44 30 5 0.35 2.0 0.40
*Inhibitory activities of the compounds were measured by using CHO transfectants as
described in Materials and Methods. Each value is the average of triplicate measure-
ments.
‡Inhibitory activities of the compounds for MMP-1 and MMP-9 were measured by
using FITC-collagen and FITC-gelatin as the substrate, respectively. These substrates
were hydrolyzed by MMP-1 and MMP-9 for 16 and 24 h, respectively, at 358C in the
presence or absence of each compound, and fluorescence intensities were measured.
Inhibitory activities of compounds for MMP-3 were measured by using a fluorogenic
peptide substrate (Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2). The
peptide was hydrolyzed by MMP-3 for 2 h at 378C in the presence or absence of each
compound, and the fluorescence intensities were measured. IC50s were calculated by
the probit method from concentration–percent inhibition curves.The Journal of Cell Biology, Volume 151, 2000 214
OSU8-1 showed superior growth and migration into the
scraped area, compared with OSU8–treated cells and con-
trol cells (Fig. 5). On the other hand, the addition of HB-
EGF to wounded keratinocytes that were also treated with
No. 425 or AG1478 had no effect on cell growth or migra-
tion (data not shown). These data suggest that OSU8-1
does not interfere directly with EGFR activation and its
downstream signaling pathway.
OSU8-1 has a broad spectrum of inhibitory activity for
MMPs (Table I). Thus, the inhibitory effects of OSU8-1
on wounded keratinocyte migration could conceivably re-
flect the suppression of other MMP-dependent events be-
sides EGFR ligand shedding. To clarify the importance of
EGFR ligand shedding in the migration of the kerati-
nocytes, we further employed two other inhibitors with al-
most the same activities for blocking EGFR-ligand shed-
ding, but distinguishable activities with regard to the
MMPs, as shown in Table I. OSU7-6 showed inhibitory ac-
tivities with IC50s of 0.35, 2.0, and 0.4 nM for MMP-1,
MMP-3, and MMP-9, respectively, which were compara-
ble to those of OSU8-1. In contrast, OSU9-6 showed ex-
tremely low activities for MMP-1, MMP-3, and MMP-9,
with IC50s of 10, 10, and .1 mM, respectively. Nonetheless,
OSU7-6 and OSU9-6 were equally effective at inhibiting
cell migration in a dose-dependent manner, blocking mi-
gration nearly 70% relative to the control at 10 mM con-
centration (Fig. 6 b).
Since the growth of keratinocytes has been shown to be
mediated by juxtacrine stimulation in addition to auto/
paracrine signals (Inui et al., 1997), we next addressed the
issue of whether OSU8-1 is capable of interfering with the
Figure 3. Production of soluble EGFR ligands and activation of
EGFR in cultured keratinocytes after wounding. (a) Detection of
shed EGFR ligands produced by wounded keratinocytes. The
levels of released EGFR ligands in conditioned media collected
at the indicated times in the presence or absence of 1 mM OSU8-1
were measured by an EP170.7 cell assay. Four independent ex-
periments were carried out and a typical time course of the level
of EGFR ligands is shown. Each bar is the average of quadrupli-
cate values. (b) Tyrosine phosphorylation of EGFR in wounded
keratinocytes. Keratinocytes, cultured in 10-cm dishes, were
stimulated by tip-scraping and incubated for the indicated times
in the presence or absence of 1 mM OSU8-1. Wounded kerati-
nocytes were lysed and subjected to immunoprecipitation with
EGFR antibodies followed by SDS-PAGE and Western blotting.
Half of the immunocomplex was used for the detection of phos-
photyrosine with PY-20 antibody, and the other half for the de-
tection of EGFR protein with EGFR antibody.
Figure 4. Characterization of EGFR-ligand shedding in kerati-
nocytes. (a) Gene expression of EGFR ligands in wounded kera-
tinocytes. After incubation of keratinocytes for the indicated
time after wounding, total RNA was extracted and analyzed by
Northern blotting. Sequential hybridization using the same mem-
brane is shown. HB-EGF (2.4 kb), AR (1.4 kb), and TGF-a (4.8
kb) messages were detected. (b) Effect of cycloheximide and
HB-EGF neutralizing antibody No. 197 on wound-induced
EGFR activation in cultured keratinocytes. Keratinocytes were
stimulated by tip-scraping in the presence or absence of cyclo-
heximide (50 mM) or HB-EGF neutralizing antibody No. 197 (10
mg/ml). After incubating for the indicated times, the cells were
lysed and subjected to immunoprecipitation with EGFR antibod-
ies, fractionation by SDS-PAGE, and Western blotting. Half of
the immunocomplex was used for the detection of tyrosine phos-
phorylation with phosphotyrosine antibody PY-20, and the other
half for detection of EGFR protein with EGFR antibody. Cyclo-
heximide (50 mM) did not abrogate the wound-induced tyrosine
phosphorylation of EGFR. On the other hand, antibody No. 197
(10 mg/ml) suppressed wound-induced tyrosine phosphorylation
of EGFR by 70%. (c) Quantitative analyses of EGFR ligand
shedding. Stable transfectants of HaCat cells expressing nearly
equal amounts of AP-tag HB-EGF, AP-tag AR, or AP-Tag
TGF-a were incubated with or without 1 mM OSU8-1 for 60 min
after wounding. AP activities in the conditioned media were
measured. Each bar is the average of triplicate values.Tokumaru et al. Ectodomain Shedding of HB-EGF in Wound Healing 215
juxtacrine growth activity of EGFR ligands on the cell
surface of keratinocytes in culture. As shown in Fig. 7
a, OSU8-1 actually slightly upregulated the juxtacrine
growth activity of keratinocytes, a finding which could be
due to the accumulation of membrane-anchored EGFR
ligands produced in the presence of OSU8-1. In un-
wounded keratinocyte cultures, OSU8-1 inhibited 50% of
the cell growth, a significantly less effective inhibition than
that seen with No. 425 and AG1478 (Fig. 7 b). Taken to-
gether, these results are consistent with a model wherein
OSU8-1 suppresses cell growth mediated by soluble
EGFR ligands, with cell growth in the presence of OSU8-1
accounted for by juxtacrine stimulation.
To quantify more directly the inhibitory effect of OSU8-1
on keratinocyte autocrine motility, the migratory activity
of keratinocyte conditioned medium collected 48 h after
wounding in the presence or absence of OSU8-1 was mea-
sured using a Boyden chamber. As a positive control, re-
combinant HB-EGF was tested and shown to be a potent
stimulator of keratinocyte migration in this assay, with a
maximal stimulation at 10 ng/ml (Fig. 7 c). Stimulation of
keratinocyte migration was also obtained using the condi-
tioned medium (Fig. 7 d). With undiluted conditioned me-
dium, the stimulation was comparable to that of recombi-
nant HB-EGF at 10 ng/ml. However, conditioned medium
collected in the presence of OSU8-1 was z30-fold less po-
Figure 5. Evaluation of OSU8-1
and EGFR inactivation on ke-
ratinocyte migration. A por-
tion of the keratinocytes were
removed from tissue culture
plates by scraping, and the re-
maining cells were cultured for
3 d in the absence or presence
of EGFR neutralizing anti-
body No. 425 (10 mg/ml),
EGFR kinase–specific inhibi-
tor AG1478 (30 nM), OSU8-1
(1 mM), or both OSU8-1 (1 mM)
and HB-EGF (20 ng/ml). The
same area of each dish was
monitored microscopically (403)
at day 0 and day 3.The Journal of Cell Biology, Volume 151, 2000 216
tent at promoting migration, indicating that OSU8-1
greatly reduced the production of autocrine motility fac-
tor (Fig. 7 d). To exclude unexpected effects of OSU8-1
itself on cell migration, various concentrations of OSU8-1
were added to the conditioned medium prepared from
wounded keratinocytes, and the mixtures were tested for
the migration activity. As shown in Fig. 7 e, OSU8-1 had
no effect on the migration of keratinocytes induced by the
conditioned medium of wounded keratinocytes, suggest-
ing that OSU8-1 does not interrupt the intracellular signal-
ing cascade of cell migration.
Effect of OSU8-1 on Cutaneous Wound Healing In Vivo
Under conditions of wounding, keratinocytes migrate from
hair follicles and the wound edge towards the center of the
wound. Given the effects of OSU8-1 described above on
keratinocyte migration in vitro in response to wound stim-
uli, we therefore investigated the effects of OSU8-1 on cu-
taneous wound healing in mice. Keratin staining of wound
tissue sections from wounds treated with vehicle solution
alone revealed the migration of keratinocytes into the
wounded site. Regenerated epithelium and granulation tis-
sue was observed in the upper dermis at day 6 after wound-
ing (n 5 15, Fig. 8 a). In contrast, wound tissue sections
from wounds treated with 10 mM of OSU8-1 showed essen-
tially no tissue regeneration or repair of the epidermis (Fig.
8 b). It is noteworthy that the migration of keratinocytes
into the wounded site was completely blocked in all of the
OSU8-1– treated wounds (n 5 10; Fig. 8 b). The application
of HB-EGF at 5 mg/ml in addition to OSU8-1 restored ke-
ratinocyte migration, resulting in healing wounded sites
(n 5 5; Fig. 8 c). These results indicate that the production
of the soluble forms of EGFR ligands represents a critical
event in the process of wound healing in vivo.
Figure 6. Dose effects of EGFR-Fc (a) and OSU8-1, OSU7-6,
and OSU9-6 (b) on keratinocyte migration after wounding. Each
point is the average of quadruplicate measurements. Migration
was evaluated by the distance between the furthest migrated cell
and the scraped edge.
Figure 7. Quantitative evaluation of the effects of OSU8-1 and
EGFR inactivation on keratinocyte growth and migration. (a)
Effect of 1 mM OSU8-1 on juxtacrine activity of EGFR ligands in
cultured keratinocytes. Juxtacrine activity was measured as de-
scribed in Materials and Methods. (b) The effect of OSU8-1, an-
tibody No. 425 and AG1478 on the growth of keratinocytes. Ke-
ratinocytes were seeded at a density of 105 cells/well in 6-well
plates and incubated for 3 d in the absence or presence of OSU8-1
(1 mM), antibody No. 425 (10 mg/ml), or AG1478 (30 nM). (a and
b) Values represent the average of triplicate experiments. (c)
Stimulation of keratinocyte migration by HB-EGF. The ability of
recombinant HB-EGF to stimulate keratinocyte migration was
tested using a Boyden chamber. (d) Stimulation of keratinocyte
migration by conditioned medium. Serially diluted, 48-h condi-
tioned medium obtained from wounded keratinocytes was added
to the bottom wells of Boyden chambers and tested for its ability
to stimulate keratinocyte migration. Open circles, conditioned
medium generated in the presence of 1 mM OSU8-1; closed cir-
cles, conditioned medium obtained without 1 mM OSU8-1. (e)
Effect of OSU8-1 on the migration response of keratinocytes in-
duced by conditioned medium from wounded keratinocyte cul-
tures. The indicated concentrations of OSU8-1 were added to the
top (open circles) and the bottom (closed circles) wells of a Boy-
den chamber containing wounded keratinocyte conditioned me-
dium in the bottom wells. An open triangle shows migrated cell
number obtained using fresh medium in the bottom wells as a
control. (c–e) Each point is the average of quadruplicate mea-
surements.Tokumaru et al. Ectodomain Shedding of HB-EGF in Wound Healing 217
Discussion
In primary keratinocyte cultures and skin explant models,
it has been reported that keratinocyte migration and pro-
liferation are key events and are predominantly mediated
by autocrine EGFR activation (Stoll et al., 1997). Consti-
tutive gene expression and protein production of EGFR
ligands such as HB-EGF, AR, and TGF-a from kerati-
nocytes also have been demonstrated in vivo and in vitro
(Coffey et al., 1987; Cook et al., 1991; Hashimoto et al.,
1994; Inui et al., 1997). However, the mechanisms, by
which the endogenous ligands of EGFR are regulated af-
ter wounding, and their precise roles in the wound healing
process are unclear. To address these questions, we fo-
cused on the molecular events associated with three
EGFR ligands (HB-EGF, TGF-a, and AR) and EGFR ac-
tivation in an early phase after wounding.
Production of EGFR ligands and EGFR activation by
wound stimuli in cultured keratinocytes occurred coordi-
nately and showed a biphasic pattern. The prolonged acti-
vation of EGFR is not in agreement with the previously
reported time course for transient activation and downreg-
ulation of EGFR when stimulated by exogenous ligands,
and may, therefore, be a physiological property of auto-
crine EGFR activation. The biphasic production of the
shed EGFR ligands and EGFR activation could be ac-
counted for if the first peak represents the local induction
triggered by wound stimuli, whereas the second peak rep-
resents induction regulated by an intracellular signaling
cascade (Fan and Derynck, 1999; Gechtman et al., 1999).
The fact that three types of EGFR autocrine ligands,
namely, HB-EGF, TGF-a, and AR, have been reported to
be expressed on the keratinocyte cell surface in mem-
brane-anchored forms (Inui et al., 1997) suggested that the
shedding of these ligands might be triggered by wound
stimuli. Quantitative analyses of the wound-inducible
shedding of EGFR ligands, using an AP-tag assay, re-
vealed that HB-EGF represents the factor which is most
susceptible among these three ligands for wound-induced
processing. It is interesting to speculate that the difference
in susceptibility for shedding among the three ligands
might reflect the independent physiological significance of
each factor.
We identified an inhibitor, OSU8-1, which effectively
inhibits HB-EGF, AR, and TGF-a shedding, and charac-
terized its effects on keratinocytes in vitro and in vivo. The
addition of OSU8-1 markedly prevented the shedding of
EGFR ligands induced by wound stimuli and EGFR acti-
vation in the early phase after wounding, resulting in the
inhibition of keratinocyte migration. However, OSU8-1
was less effective at inhibiting cell proliferation. Based on
the findings that the EGFR neutralizing antibody and the
EGFR kinase inhibitor AG1478 inhibited both cell migra-
tion and proliferation, and that OSU8-1 did not abrogate
the juxtacrine activity of keratinocytes, we hypothesize
that the inhibition of EGFR ligand shedding by OSU8-1
abrogates auto/paracrine stimulation by soluble EGFR
ligands, which is critical for keratinocyte migration, but
that proliferation is less affected as it can be triggered by
juxtacrine stimulation, which is mediated by membrane-
anchored EGFR ligands.
The biological significance of the juxtacrine and auto/
paracrine activities of HB-EGF has been poorly character-
ized. However, we recently reported that the juxtacrine
activity of HB-EGF specifically evoked an antiapoptotic
effect in a rat hepatoma cell line AH66tc and that trans-
membrane HB-EGF, therefore, functioned as a cell sur-
vival factor (Miyoshi et al., 1997). Cell survival in response
to HB-EGF juxtacrine stimulation also has been shown in
the case of kidney epithelial cells (Takemura et al., 1997).
Differences in the biological effects evoked by juxtacrine
and auto/paracrine activities are likely to reflect the exist-
ence of unique molecules that are recruited to each signal-
ing pathway. It has been reported that mice harboring a
knockout of Stat3 in their keratinocytes showed a signifi-
Figure 8. Effect of OSU8-1 on wound healing in vivo. Histology
of excised mouse skin on day 6 after wounding, without or with
10 mM OSU8-1 treatment. Keratinocytes were stained with anti-
keratin/cytokeratin antibody. (a) A typical tissue section from
the control wounds (n 5 15). Keratinocytes are observed to have
migrated from the edge of the wound, spreading under the crust
and covering the wound site. Arrowheads indicate the base of the
keratinocyte layer. The arrow marks the edge of the wound. (b)
A typical tissue section from an OSU8-1–treated wound (n 5 10).
Both keratinocyte migration and the regeneration of the epider-
mis were greatly inhibited. (c) A typical tissue section from a
wound treated with a cocktail of OSU8-1 and HB-EGF (5 mg/ml;
n 5 5). Both keratinocyte migration and the regeneration of the
epidermis were completely restored.The Journal of Cell Biology, Volume 151, 2000 218
cant retardation of cutaneous wound healing as reflected
in a lack of keratinocyte migration. However, the growth
response of the keratinocytes in these mice to several
growth factors appeared to be normal (Sano et al., 1999).
Consistent with these observations, we found that specific
activation of Stat3 was evoked by EGFR ligand shedding
in cultured keratinocytes (data not shown), suggesting that
the ectodomain shedding of EGFR ligands could trigger
intercellular signaling pathways unique for auto/paracrine
and juxtacrine stimulation.
Analyses of the effects of OSU8-1 on cutaneous wound
healing in vivo revealed that wounded tissue sections
treated with 10 mM OSU8-1 showed essentially no tissue
regeneration and repair at day 6 after wounding. In partic-
ular, there was a marked lack of keratinocyte migration, as
compared with cutaneous healing in control mice. Admin-
istration of recombinant HB-EGF, in addition to OSU8-1,
restored the migration of keratinocytes in wounded sites.
Therefore, we conclude that the shedding of EGFR
ligands represents a crucial event in the migration of kera-
tinocytes to the wound site in vivo. The present findings
may also have implications not only for our understanding
of the molecular mechanism involved in wound healing,
but also for other tissue remodeling processes such as tro-
phoblast invasion, inflammatory diseases, and, in particu-
lar, tumor invasion.
Recently, it has been reported that the broad spectrum
inhibition of MMPs by a synthetic inhibitor (galardin) in
plasminogen-deficient mice completely arrested wound
healing, suggesting an essential role for matrix-degrading
proteases in wound healing (Lund et al., 1999). Since
galardin, like OSU8-1, is a peptide-based zinc-chelating
hydroxamate, it might inactivate not only the MMP fam-
ily, but also the ADAM (a disintegrin and a metallopro-
tease) family involved in EGFR ligand shedding. Thus, we
speculate that the inhibition of wound healing reported by
Lund et al. (1999) might, in part, have been due to the in-
hibition of EGFR ligand shedding.
Tumor necrosis factor–a converting enzyme (TACE)
represents an additional protein involved in ectodomain
shedding. Its gene has been cloned (Black et al., 1997;
Moss et al., 1997) and disrupted (Peschon et al., 1998), re-
sulting in skin and eye defects. This phenotype resembles
that of TGF-a knockout mice, suggesting that TACE
might function widely as a shedding enzyme beyond its ef-
fects on tumor necrosis factor–a processing. TACE is now
classified in the ADAM family, which is comprised of at
least 31 members. Our most recent studies of inhibitors for
EGFR ligand shedding indicate that .1 shedding protease
could be involved in the shedding of EGFR ligands (Endo,
T., and S. Higashiyama, unpublished data). The identifica-
tion of shedding enzymes for many types of cell-surface
proteins, including receptors and ligands, would be a key
step in understanding the normal and pathological tissue
remodeling processes described above.
Recently, molecular mechanism in the ectodomain
shedding of EGFR ligands including HB-EGF and TGF-a
have been vigorously studied, showing the involvement of
MMP-3 (Suzuki et al., 1997), meltrin-g/MDC9/ADAM9
(Izumi et al., 1998), and the MAP kinase cascade (Fan and
Derynck, 1999; Gechtman et al., 1999). Further, it also has
been shown that the ectodomain shedding of HB-EGF
is a crucial step in the transactivation of the EGFR via
G-protein–coupled receptors (Prenzel et al., 1999). Taken
together with our results herein, it is clear that the
ectodomain shedding of EGFR ligands is a regulated mo-
lecular event involved in different types of physiological
and pathological phenomena.
In conclusion, wound stimuli trigger EGFR ligand shed-
ding, which represents an essential step in the cutaneous
wound healing process. OSU8-1 inhibits the shedding of
EGFR ligands, resulting in the strong inhibition of wound
healing in vitro and in vivo. It is clear that shedding en-
zymes and their involvement in wound healing are deserv-
ing of further investigation.
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